Amira Pharmaceuticals has announced positive results from a Phase I clinical study of AM152, a LPA1 receptor antagonist for the treatment of idiopathic pulmonary fibrosis.

Isabelle DeArmond, vice-president of clinical development at Amira Pharmaceuticals, said that the Phase I clinical study in healthy volunteers showed that AM152 is safe and well-tolerated at doses that are expected to provide a full range of receptor coverage in humans.

“These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases,” DeArmond said.

Amira is planning to initiate the Phase IIa study in patients suffering from systemic sclerosis, a fibrotic disease, by early 2012.